Consistent with our previous RNA sequencing data, our current study showed that a specific NOD1 inhibitor prevented PGN-induced bone marrow neuropathy and HSPC deprivation, further confirming the critical role of NOD1 in PGN-mediated bone marrow defects in subjects with diabetes. Here, NOD1 is linked to diabetes mellitus.